Combinations of Pharmacologic Smoking Cessation Treatments

This study has been completed.

First Received on July 3, 2001. Last Updated on January 20, 2009 History of Changes

Sponsor:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018187

Purpose

The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.

Condition	Intervention	Phase
Smoking	Drug: Bupropion Drug: Mecamylamine Drug: Nicotine Patch	Phase I

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Combinations of Pharmacologic Smoking Cessation Treatments

Resource links provided by NLM:

MedlinePlus related topics: Quitting Smoking Smoking

Drug Information available for: Mecamylamine Nicotine tartrate Bupropion hydrochloride Bupropion Nicotine polacrilex Mecamylamine hydrochloride

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	November 1998
Estimated Study Completion Date:	June 2001

Eligibility

Ages Eligible for Study:	20 Years to 40 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Subjects must be a smoker between 20 and 40 years old, have smoked at least 20 cigarettes per day for at least 2 years, wish to stop smoking and be in good general health

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018187

Locations

United States, California
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073

Sponsors and Collaborators

Department of Veterans Affairs

Investigators

Investigator:

Neil Hartman, M.D.

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00018187 History of Changes
Other Study ID Numbers:	ADRD-011-98S
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
Health Authority:	United States: Food and Drug Administration

Keywords provided by Department of Veterans Affairs:

smoking cessation
bupropion
mecamylamine
nicotine

Additional relevant MeSH terms:

Smoking
Habits
Mecamylamine
Nicotine
Nicotine polacrilex
Bupropion
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Ganglionic Blockers
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Antagonists

Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Ganglionic Stimulants
Nicotinic Agonists
Cholinergic Agonists
Central Nervous System Stimulants
Central Nervous System Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Uptake Inhibitors

ClinicalTrials.gov processed this record on February 12, 2012